

Here to help throughout your **ZYMFENTRA**[™] (infliximab-dyyb) treatment journey from intravenous (IV) infliximab to a self-administered subcutaneous injection



HOW TO GET STARTED

Work with your healthcare provider (HCP) to enroll in Celltrion CONNECT[®].

There are 2 ways to enroll:



Online

Your HCP can enroll you through an easy online portal or send an ePrescription from their office

OR



Fax

You and your HCP can download, complete, and sign the enrollment form. Your HCP will then fax the completed form to **833-912-3707**

You can download the enrollment form, as well as review and sign by going to CelltrionConnect.com/ZYMFENTRA and click on "Patient Consent"

Scan here to sign the patient consent form:



Personalized Support

Celltrion CONNECT provides personalized support for patients prescribed ZYMFENTRA. A dedicated Celltrion CONNECT Case Coordinator provides 1:1 support to help patients shift from IV infliximab to ZYMFENTRA, including:

- Information on how your insurance covers ZYMFENTRA and **what it will cost you**
- Access to Celltrion CONNECT programs to **help you pay** for ZYMFENTRA, if eligible
- **Nurse Connector[™] support** to help you transition from IV infliximab to ZYMFENTRA and provide supplemental training on how to administer it

Please see Medication Guide, including Boxed Warning.

Once enrolled, your dedicated **Celltrion CONNECT Case Coordinator** will help you:



Understand Your Insurance Coverage

Case Coordinators will confirm your insurance coverage for ZYMFENTRA[™] (infliximab-dyyb) and your out of pocket (OOP) costs. They will determine if your insurer requires additional prior authorization (PA). The Case Coordinators can also work with your HCP to help resolve any issues with insurance approvals.



Connect to Nursing Support Resources

Your Case Coordinator will pair you with a **Nurse Connector**[™] who can help you get started and stay on track with your prescribed treatment. Nurse Connectors can provide you:*

- Product and disease state education to learn more about your condition
- Support in the transition from IV infliximab to ZYMFENTRA
- Supplemental training on how to use your injection device
- Tools and resources to assist with injection site rotation and dosing schedule

CELLTRION
nurseconnector
Connecting Through the Treatment Journey



Review Financial Assistance Options

All patients enrolled in Celltrion CONNECT will be screened for financial assistance eligibility. A Case Coordinator will help connect you to the right financial assistance program.

Patients with commercial insurance coverage may pay as little as **\$5 per month** through the Celltrion CARES[™] Co-pay Assistance Program. Patients with federally funded health insurance like Medicare or Medicaid are not eligible for this program. View complete program rules and enroll online at www.CelltrionCares.com.

If you do not have insurance or have commercial insurance that does not cover ZYMFENTRA, you may be able to get ZYMFENTRA at no cost through Celltrion CONNECT:[†]

- Eligibility is restricted to patients with commercial insurance who have been prescribed ZYMFENTRA for an FDA-approved indication
- Program participation is in no way contingent on any requirement or obligation to purchase ZYMFENTRA or any other Celltrion product or service
- Eligibility for continued participation will be verified periodically, and patients will not be eligible to continue participating if they no longer satisfy the eligibility criteria, including when initiation of coverage for ZYMFENTRA is approved by the patient's commercial insurance plan

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call **1-800-FDA-1088**.

Please see Medication Guide, including Boxed Warning [here](#).

*Participation in the Nurse Connector program is voluntary. Patients can opt out of this service at any time. Nurse Connectors will not offer medical advice and will always refer the patient back to the prescriber for any questions specific to their treatment.

[†]Celltrion may provide ZYMFENTRA to eligible patients, including those with commercial insurance experiencing delays or a gap in coverage of ZYMFENTRA. Eligible patients must have been prescribed ZYMFENTRA for an FDA-approved indication, and their participation is in no way contingent on any requirement or obligation to purchase ZYMFENTRA or any other Celltrion product or service at any time. Patients who are covered, in whole or part, through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs, or Department of Defense are not eligible. Eligibility for continued participation will be verified periodically, and patients will not be eligible to continue participating if they no longer satisfy the eligibility criteria, including when initiation of coverage for ZYMFENTRA is approved by the patient's commercial insurance plan. This offering will end on December 31, 2024. Void where prohibited or restricted by law, and Celltrion reserves the right to rescind, revoke, or amend the terms and conditions at any time without notice.